Goldman Sachs Group Inc Cor Medix Inc. Transaction History
Goldman Sachs Group Inc
- $780 Billion
- Q3 2025
A detailed history of Goldman Sachs Group Inc transactions in Cor Medix Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 230,810 shares of CRMD stock, worth $2.62 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
230,810
Previous 196,601
17.4%
Holding current value
$2.62 Million
Previous $2.42 Million
14.04%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CRMD
# of Institutions
204Shares Held
41.2MCall Options Held
1.33MPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA3.98MShares$45.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$40.3 Million0.0% of portfolio
-
Marshall Wace, LLP London, X03.47MShares$39.4 Million0.05% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.32MShares$37.7 Million0.74% of portfolio
-
State Street Corp Boston, MA1.84MShares$20.8 Million0.0% of portfolio
About CorMedix Inc.
- Ticker CRMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,208,200
- Market Cap $467M
- Description
- CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...